Log In
Print
BCIQ
Print
Print this Print this
 

CEP-32496

  Manage Alerts
Collapse Summary General Information
Company Daiichi Sankyo Co. Ltd.
DescriptionSmall molecule BRAF kinase inhibitor
Molecular Target BRAF
Mechanism of ActionBRAF inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationMelanoma
Indication DetailsTreat melanoma
Regulatory Designation

Partner

Teva Pharmaceutical Industries Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today